Showing results (291-300 of 389) with videos related to
Sort By:
Pageof 39
Cells|September 28, 2021
Dynamic, Transient, and Robust Increase in the Innervation of the Inflamed Mucosa in Inflammatory Bowel DiseasesMiguel Gonzalez Acera, Marvin Bubeck, Fabrizio Mascia, et al.Journal of Crohn'S & Colitis|August 4, 2016
Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal LesionsKenji Suzuki, Junji Yokoyama, Yusuke Kawauchi, et al.Gastroenterology|August 31, 2011
Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophagesRaja Atreya, Michael Zimmer, Brigitte Bartsch, et al.The Lancet. Gastroenterology & Hepatology|October 14, 2022
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trialWilliam J Sandborn, Julian Panés, Silvio Danese, et al.Journal of Clinical Medicine|February 7, 2020
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by VedolizumabPatrizio Scarozza, Irene Marafini, Federica Laudisi, et al.United European Gastroenterology Journal|May 9, 2026
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative ColitisAilsa Hart, Seyedehsan Navabi, Geert D'Haens, et al.Nature Communications|February 3, 2024
Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cellsMaximilian Wiendl, Mark Dedden, Li-Juan Liu, et al.BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.Journal of Crohn'S & Colitis|March 25, 2025
Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustmentBernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, et al.Gastroenterology|March 27, 2017
Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel DiseaseMircea T Chiriac, Barbara Buchen, Alexandra Wandersee, et al.Pageof 39